PPARs, metabolic disease and atherosclerosis

被引：91

作者：

Fruchart, JC

Staels, B

Duriez, P

机构：

[1] Univ Lille 2, F-59800 Lille, France

[2] Inst Pasteur, INSERM, U545, Dept Atherosclerose, F-59019 Lille, France

[3] Inst Pasteur, INSERM, U545,Fac Pharm, Unite Rech Lipoprot & Atherosclerose, F-59019 Lille, France

来源：

PHARMACOLOGICAL RESEARCH | 2001年 / 44卷 / 05期

关键词：

PPAR-alpha; lipoprotein metabolism; atherosclerosis; metabolic disease;

D O I：

10.1006/phrs.2001.0871

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

PPAR-alpha belongs to the family of nuclear receptors. Activated PPAR-alpha stimulates the expression of genes involved in fatty acid and lipoprotein metabolism. PPAR-alpha activators, such as the normolipidaemic fibric acids, decrease triglyceride concentrations by increasing the Zn expression of lipoprotein lipase and decreasing apo C-III concentration. Furthermore, they increase HDL-cholesterol by increasing the expression of apo A-I and apo A-II. PPAR-alpha activation by fibric acids improves insulin sensibility, and decreases thrombosis and vascular inflammation, PPAR-alpha activators (gemfibrozil) decrease the risk of coronary heart disease in patients with normal LDL-cholesterol and low HDL-cholesterol (VA-HIT) and they slow the progression of premature coronary atherosclerosis (BECAIT) (bezafibrate), particularly in patients with type 2 diabetes (DAIS) (fenofibrate). (C) 2001 Academic Press.

引用

收藏

页码：345 / 352

页数：8

相关论文

共 65 条

[11] MODULATION OF LIPOPROTEIN B BINDING TO THE LDL RECEPTOR BY EXOGENOUS LIPIDS AND APOLIPOPROTEIN-CI, APOLIPOPROTEIN-CII, APOLIPOPROTEIN-CIII, AND APOLIPOPROTEIN-E [J].

CLAVEY, V ;

LESTAVELDELATTRE, S ;

COPIN, C ;

BARD, JM ;

FRUCHART, JC .

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1995, 15 (07) :963-971

[12]

Colville-Nash PR, 1998, J IMMUNOL, V161, P978

[13]

DEFAIRE U, 1995, DRUG EXP CLIN RES, V21, P105

[14] Secondary preventive potential of lipid-lowering drugs - The Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT) [J].

deFaire, U ;

Ericsson, CG ;

Grip, L ;

Nilsson, J ;

Svane, B ;

Hamsten, A .

EUROPEAN HEART JOURNAL, 1996, 17 :37-42

[15] Peroxisome proliferator-activated receptor α negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-κB and AP-1 [J].

Delerive, P ;

De Bosscher, K ;

Besnard, S ;

Vanden Berghe, W ;

Peters, JM ;

Gonzalez, FJ ;

Fruchart, JC ;

Tedgui, A ;

Haegeman, G ;

Staels, B .

JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (45) :32048-32054

[16] The PPAR alpha-leukotriene B-4 pathway to inflammation control [J].

Devchand, PR ;

Keller, H ;

Peters, JM ;

Vazquez, M ;

Gonzalez, FJ ;

Wahli, W .

NATURE, 1996, 384 (6604) :39-43

[17] Effects of two different fibric acid derivatives on lipoproteins, cholesteryl ester transfer, fibrinogen, plasminogen activator inhibitor and paraoxonase activity in type IIb hyperlipoproteinaemia [J].

Durrington, PN ;

Mackness, MI ;

Bhatnagar, D ;

Julier, K ;

Prais, H ;

Arrol, S ;

Morgan, J ;

Wood, GNI .

ATHEROSCLEROSIS, 1998, 138 (01) :217-225

[18] Chylomicronemia due to apolipoprotein CIII overexpression in apolipoprotein E-null mice - Apolipoprotein CIII-induced hypertriglyceridemia is not mediated by effects on apolipoprotein E [J].

Ebara, T ;

Ramakrishnan, R ;

Steiner, G ;

Shachter, NS .

JOURNAL OF CLINICAL INVESTIGATION, 1997, 99 (11) :2672-2681

[19] Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients [J].

Ericsson, CG ;

Hamsten, A ;

Nilsson, J ;

Grip, L ;

Svane, B ;

deFaire, U .

LANCET, 1996, 347 (9005) :849-853

[20] Effect of bezafibrate treatment over five years on coronary plaques causing 20% to 50% diameter narrowing (The Bezafibrate Coronary Atherosclerosis Intervention Trial [BECAIT]) [J].

Ericsson, CG ;

Nilsson, J ;

Grip, L ;

Svane, B ;

Hamsten, A .

AMERICAN JOURNAL OF CARDIOLOGY, 1997, 80 (09) :1125-1129

← 1 2 3 4 5 6 7 →